2013 - 2018 small peptides industry in China market trend analysis and investment strategy decision-making report (authority) ------------------------------ ---------------------------- [Report No.: 66064 〖〗: institutions, published in May 2013 〖〗: Beijing Industry Information Institute [delivery〗: Email electronic version or EMS [Report Price]: [paper version]: 6500 yuan [electronic version]: 6800 yuan [paper + E]: 7000 yuan [Order Tel]: 010 - Fax 57101558 010-52891825 〖Order〗: 010-84953789 〖〗 straight line phone: 15001081554 〖QQ Order〗: 1607366836 〖Contact〗: the Hooley Yang Cheng Kam Lai 〖link〗 http://www.bjcyxxyjy.com/qitaxingye/ qita/66064.html Table of Contents Chapter the 2012 small peptides Summary of the development of the industry 18 Section the small peptides industry defined 18, 18 of the economic characteristics of the industry, Main products / industry segments 19 Third, the industry chain structure analysis 20 Section II peptide industry maturity of 23, the development of the industry cycle analysis 23 Second, the industry of Chinese and foreign market maturity contrast 25 Third, the industry and its major sub-sectors maturity analysis 25 Chapter 2013-2018 Chinese enterprises of small peptides PEST (environmental) 27 Section I Analysis of Economic Environment 27 Section II Analysis on Policy Environment 42 Section III Social Environment 44 Section IV environmental analysis 49 Chapter 3 small peptide production technology industry analysis 50 first small peptides industry production technology development status 50 Section II small peptides industry production process characteristics or process 50 Section III the small peptides industry production technology development trend analysis 53 Chapter 55 Section 2012 the small peptide enterprise development enterprises of small peptides Development Analysis 55, 2012 business operation and characteristics of small peptides 55, 2012 the small peptides enterprise investment analysis of 55 Chinese the small peptide enterprise product structure analysis 56 2.4 small peptide enterprise in China and macroeconomic analysis 56 Section II China regional development analysis of 56 enterprises focus on the characteristics of the regional distribution and change 56, 56 3 of North China, East China 57, Northeast Market Analysis 5 57 58 Saturday, Central South Market, Western Market Analysis 58 in the South China market market analysis 58 Chapter 2012 the China market supply and demand of small peptides investigation analysis 60 Section 2012 market supply analysis of small peptides 60, 60 products market supply, price supply 60 three-channel supply 61 section 2012 small peptides market demand analysis 61, 61 of the market demand, the price needs 62 channels demand 63, 65 purchasing needs 63 third 2012 market analysis of small peptides, small peptides 2012 product characteristic analysis 65, 2012 the small peptide Price characteristics analysis of 66, 66 of the channel characteristics of small peptides in 2012, 2012, China's small peptides to purchase features 66 Chapter 6 2012 small peptides enterprise market competition pattern analysis of 68 section concentration analysis of small peptide enterprise in China in 2012, the second in 2012, 68 Chinese the small peptide enterprise scale economic pattern of small peptide enterprises in China as well as the competitive situation analysis of the third quarter 2012 68 69, their overall competitive landscape and trend analysis 69 Second, regional market competition and trend analysis of the fourth quarter 69 Chinese enterprises to enter and exit barriers analysis 70 70 Chapter 7, Section V 2012 small peptide enterprise in China main advantage of comprehensive evaluation of the competitiveness of enterprises in 2012 a small peptide main competitor analysis 71 first gold source in Qinghai Biological Products Co., Ltd. 71 Company Profile 71 major economic indicators of 72 Section II Analysis Lingwu Thailand shipped Biochemical Products Co., Ltd. 77 Company Profile 77, major economic indicators of 78 the third quarter the Opp oligopeptide Institute of Technology, in Beijing 83 a, Company Profile 83 Second, analysis of major economic indicators of 84 Section IV Ningxia Qin Biotechnology Co., Ltd. 90 a Company Profile 90 Second, analysis of major economic indicators of 91 Section V Hubei Ho Bio-Technology Co., Ltd. 96 a Company Profile 96 Second, the major economic indicators of 97 Section VI is Wuhan Wei Biotechnology Co., Ltd. 102 1, 102 of the Company Profile, major economic indicators of analysis of 103 first seven Wenzhou peptide Kang Biotechnology Co., Ltd. 109 I. About 109 enterprises of major economic indicators analysis 110 Section VIII Beijing Sheng Miele Biotechnology Co., Ltd. 115 Company Profile 115 Second, the major economic indicators of analysis of 116 first nine Qingzhou Lombe Biotechnology Co., Ltd. 121 I. About 121 enterprises of major economic indicators analysis 128 Chapter 122 Section X the heroic era Technology Co., Ltd. 127 Company Profile 127, major economic indicators of analysis 2013 -2018 upstream and downstream industry chain analysis in small peptide enterprise in China and its impact on the first 2012 135 Chinese the small peptide enterprise upstream enterprise development and impact analysis of 135 Chinese the small peptide enterprises upstream firm running status analysis 135 in 2012, the enterprise impact analysis of the second 2012 137 137 Chinese the small peptide enterprise downstream enterprise development and impact analysis, run Analysis of 2012 Chinese enterprises and downstream enterprises of small peptides 137, the impact of the enterprise 142 Section 3 Other enterprise development and impact analysis 142 Chapter 2013-2018 Chinese the small peptide enterprise development trend forecast policy trends forecast 147 145 Section II 2013-2018 trends in supply and demand forecasts, product supply forecast 147 145 Section 2013-2018 product demand forecast for 2013-2018 148 Section III, import and export trend forecasting technology trends of the fourth quarter 2013-2018 148 2013-2018 148 Section V competitive trends forecast 148 Chapter 2013-2018 peptide enterprise investment potential and value analysis 150 Section 2013-2018 the small peptides enterprises to invest in environmental analysis 150 Section II, 2013-2018, small peptides Business SWOT model 151, 151 of the advantages, disadvantages 152 Third, the opportunity to 152 four, 153 first-threatening three investment potential analysis of small peptide enterprise in China in 2013-2018 153 Section IV 2012-2017 of small peptides enterprises in China Prospects 154 Section V 2012-2017 analysis of small peptides profitability forecast 154 Chapter 11 2013 - 2018 small peptides enterprise investment risk warning 155 Section 155 Section II of the policy and institutional risk the risk of macroeconomic fluctuations 156 Section 156 Section IV market risk technology risk 157 Section 6 157 Section V raw material pressure risk analysis market competition risk 157 Section VII of foreign capital into the current situation and the threat of future market 158 ??Section VIII marketing risks related to enterprise risk 159 Section 10 159 Section IX Regional Risk 160 160 Section XII of the Section XI risk of a shortfall Risk Analysis 160 the Section XIII management risk analysis 161 Chapter 12 2013-2018 the small peptides industry investment opportunities and investment strategy analysis of small peptide enterprise regional investment opportunities in the first 2013-2018 162 2013-2018 162 Section 2 small peptide enterprise main investment opportunities in small peptide enterprises export market investment opportunities in 2013-2018 163 Section 3 163 Section 4 2013-2018 163 of the Chinese the small peptide enterprise investment strategy, product positioning strategy 163 Second, product development strategy 164 three channel sales Strategy 165 Fourth, brand management strategy 165 Friday, service strategy 166 Chapter 13 small peptides industry enterprises synthesis of the views and experts recommend 167 first view of companies Summary 167 Section II expert investment advice 167 Table of Figures Figure 1 industry chain formation pattern diagram 21 Figure 2 peptide in which the industrial industry life cycle diagram 23 Figure 3 Industry Life Cycle strategy and its characteristics 25 Figure 4 2011-2012 year growth rate of GDP (%) 27 Figure 2011-2012 China's consumer price index (CPI) 27 chart 61978-2011 urban and rural Engel coefficient comparison table 30 Chart 7 2011-2012 camp cumulative total business revenue and profit year-on-year growth rate of 33 chart 82011-2012 accumulated each month per 100 yuan the cost of main business income margin of 33 chart in the main business income of 92 012 respectively, year-on-year growth rate of the main business income and total profit of the economic type 34 Exhibit 10 2011-2012 investment in fixed assets (excluding farmers) year-on-year growth 35 Exhibit 11 2012 respectively, adjacent to the area on two months cumulative year-on-year growth rate of 36 Chart 12 2011-2012 capital in place of year-on-year growth rate of investment in fixed assets 37 Figure 13 2012 1-12 month investment in fixed assets (excluding farmers) data 37 Chart 14 2011-2012 Total sales of consumer goods monthly year-on-year growth rate of 39 chart 15 December 2012 the total retail sales of social consumer goods data 40 Figure 16 morphine-like activity of small peptides from different proteins 51 Figure 17 using phage display activity Some examples of peptides and peptide mimetics 52 Chart 18 2010-2012 China's small peptide growth rate of business investment analysis 55 Figure 19 of small peptides enterprises in China regional distribution analysis 56 Exhibit 20 2011-2012 North China the small peptides industry production and marketing capacity analysis 56 Chart 21 2011-2012 East China the small peptides industry industry production and marketing capacity of 57 chart the 22 2011-2012 northeast region of small peptides industry production and marketing capacity analysis 58 Exhibit 24 2011 57 Chart the 23 2011-2012 SOUTH small peptides industry production and marketing capacity analysis - 2012 the western region of small peptides industry production and marketing capacity of 58 Exhibit 25 2011-2012 South China the small peptides industry production and marketing capacity 58 Chart 26 2010-2012 China small peptides market supply and demand analysis 60 Exhibit 27 of small peptides industry in China downstream consumer prices emphasis on analysis of 62 Chart 28 2007-2012 China's small peptides industry sales revenue and growth of 68 chart of small peptides industry sales trends 29 2007-2012 69 Chart 30 nearly four years Qinghai Biological Products Co., Ltd. Current assets turnover number of changes 72 Exhibit 31 for nearly four years Qinghai Jinyuan Biochemical Products Co., Ltd. Current assets turnover frequency change 72 Exhibit 32 for nearly four years Qinghai Biological Products Co., Ltd. equity ratio change 73 Exhibit 33 for nearly four years Qinghai source of biological products Limited equity ratio changes 73 Exhibit 34 for nearly four years Qinghai Biological Products Co., Ltd. sales gross margin change 74 Exhibit 35 for nearly four years Qinghai Biological Products Co., Ltd. gross margin changes 74 Figure 36 nearly four years Qinghai gold Bio-Products Co., Ltd. asset-liability ratio changes 74 Figure 37 nearly four years Qinghai Biological Products Co., asset-liability ratio changes 75 chart 38 for nearly four years Qinghai Biological Products Co., Ltd. Total asset turnover frequency change 75 Chart 39 nearly four years Qinghai Jinyuan Biochemical Products Co., Ltd. Turnover of total assets change 76 Exhibit 40 for nearly four years Qinghai Jinyuan Biological Products Co., Ltd. the fixed asset turnover 76 Exhibit 41 for nearly four years Qinghai Biological Products Co., Ltd. Fixed Assets Turnover number of changes 77 Figure 42 nearly four years Lingwu Thailand shipped Biochemical Products Co., Ltd. Turnover of Working Capital changes 78 Exhibit 43 for nearly four years Lingwu Thailand shipped Biochemical Products Co., Ltd. Turnover of Working Capital changes 78 chart 44 for nearly four years Spirit Wu Tai Wan Biochemical Products Co., Ltd. equity ratio changes 79 chart 45 for nearly four years the Lingwu City the Thai Express Biochemical Products Co., Ltd. equity ratio changes 79 chart 46 for nearly four years Lingwu Thailand shipped Biochemical Products Co., Ltd. gross margin changes 79 chart 47 nearly four years the Lingwu Thailand shipped Biochemical Products Co., Ltd. gross margin changes 80 Figure 48 nearly four years Lingwu City, Thailand shipped Biochemical Products Co., Ltd. Turnover of total assets changes 80 chart 49 for nearly four years the Lingwu Taiyun biochemical Products Co., Turnover of total assets of the Company changes 81 chart nearly 4 years 50 the Lingwu Thailand shipped Biochemical Products Co., Ltd. asset-liability ratio changes 81 chart nearly 4 years 51 the Lingwu Thailand shipped Biochemical Products Co., Ltd. asset-liability ratio changes 82 Figure 52 4 Lingwu Thai shipped Biochemical Products Co., the number of fixed asset turnover 82 Figure 53 nearly four years Lingwu Thailand shipped Biochemical Products Co., Ltd. is the number of fixed asset turnover 82 Figure 54 nearly four years in Beijing Opp oligopeptide Institute of Technology flow changes in asset turnover 84 Exhibit 55 for nearly four years Johnson Opp oligopeptide Institute of Technology Current assets turnover frequency change of 85 Figure 56 nearly four years Beijing the Opp oligopeptide Health Institute of Technology equity ratio changes 85 Figure 57 nearly four years Beijing Health the Opp oligopeptide Institute of Technology equity ratio changes 85 Figure 58 nearly four years Opp oligopeptide Institute of Technology, Beijing Health sales gross margin changes 86 chart 59 for nearly four years in Beijing Opp oligonucleotide peptide Institute of Technology gross profit margin changes 86 chart 60 for nearly four years in Beijing Opp oligopeptide Institute of Technology Turnover of total assets change 87 chart 61 for nearly four years total assets turnover Opp oligopeptide in Beijing Institute of Technology number of changes 87 chart nearly 4 years 62 the Opp oligopeptide technology in Beijing Institute of asset-liability ratio changes 88 chart 63 nearly four years the Opp oligopeptide Institute of Technology, Beijing students gearing ratio of the change 88 Figure 64 4 the Beijing Health Opp oligopeptide Institute of Technology fixed assets turnover times 89 Exhibit 65 for nearly four years in Beijing Opp oligopeptide Institute of Technology fixed assets turnover times 89 chart 66 for nearly four years Ningxia Qin Biotechnology Co., Ltd. change of the current assets turnover 91 Figure 67 nearly four years Ningxia Qin Biotechnology Co., Ltd. current assets turnover changes 91 chart Ningxia Qin Biotechnology Co., Ltd. equity ratio changes 92 Exhibit 69 of 68 for nearly four years nearly four years Ningxia Qin Rong Biological Technology Co., Ltd. equity ratio changes 92 Figure 70 nearly four years Ningxia Qin Biotechnology Co., Ltd. sales gross margin change 92 chart 71 for nearly four years Ningxia Qin Biotechnology Co., Ltd. sales gross margin changes 93 Figure 72 4 asset-liability ratio of Biological Science and Technology Co., Ltd. Ningxia Qin change 93 chart 73 for nearly four years Ningxia Qin Biotechnology Co., Ltd. asset-liability ratio changes 94 Chart 74 nearly 4 years Ningxia Qin Biotechnology Co., Ltd. Turnover of total assets case 94 chart 75 for nearly four years Ningxia Qin Biotechnology Co., Ltd. Total asset turnover frequency changes 95 Figure 76 nearly four years Ningxia Qin Biological Technology Co., Ltd., fixed assets turnover times 95 Figure 77 nearly four years Ningxia Qin Biotechnology Co., Ltd. fixed asset turnover number of 96 chart 78 for nearly four years Hubei Ho Biotechnology Co., Ltd. changes in current assets turnover of 97 chart 79 for nearly four years Hubei Ho Bio-Technology Co., Ltd. changes in current assets turnover 97 Figure 80 nearly four years Hubei Ho source Biotechnology Co., Ltd. equity ratio changes 98 chart 81 for nearly four years Hubei the Melco source Biotechnology Co., Ltd. equity ratio changes 98 chart 82 for nearly four years Biotechnology Co., Ltd., Hubei Ho changes in the gross profit margin of 98 chart 83 4 years Biotechnology Co., Ltd., Hubei Ho changes in the gross profit margin of 99 chart 84 for nearly four years Hubei Ho Source Biotechnology Co., Ltd. asset-liability ratio changes 99 chart Biotechnology Co., Ltd. Hubei Ho source asset-liability ratio of nearly 4 years, 85 change 100 chart 86 for nearly four years Hubei Ho source Biotechnology Co., Ltd. Turnover of total assets changes 100 chart 87 for nearly four years Hubei Ho source Biotechnology Co., Ltd. Turnover of total assets changes 101 Figure 88 for nearly four years Hubei Ho source Biotechnology Co., Ltd. the number of fixed asset turnover 101 Figure 89 for nearly four years Hubei Ho Bio-Technology Co., Ltd., the fixed assets turnover times 101 chart for nearly four years, 90 Wuhan Yue Wei Biotechnology Co., Ltd. current assets turnover changes 103 chart 91 nearly 4 Wuhan Wei Biotechnology Co., Ltd. Current assets turnover frequency change 103 chart for nearly four years, 92 Wuhan Yue Wei Biotechnology Co., Ltd. equity ratio changes 104 chart Wuhan nearly 4 years, 93 months Wei Biotechnology Co., Ltd. equity ratio changes 104 chart 94 4 Wuhan months Wei Biotechnology Co., Ltd. sales gross margin changes 105 Figure 95 for nearly four years Wuhan Yue Wei Biotechnology Co., Ltd. sales gross margin changes 105 Figure 96 for nearly four years Wuhan months Wei Biotechnology Co., Ltd., asset-liability ratio changes 106 chart changes in Wuhan Yue Wei Biotechnology Co., Ltd. asset-liability ratio of nearly four years, 97 106 chart Wuhan Yue Wei Biotechnology Co., Ltd. Turnover of total assets changes nearly 4 years, 98 107 Figure 99 for nearly four years Wuhan Yue Wei Biological Technology Co., Ltd. Total changes in asset turnover 107 Exhibit 100 nearly four years is Wuhan Wei Biological Technology Co., Ltd. of fixed assets turnover times 108 chart for nearly four years, 101 Wuhan Yue Wei Biotechnology Co., Ltd. fixed assets turnover frequency changes 108 chart for nearly four years, 102 Wenzhou peptide Uni-Bio Science Co., Ltd. Current assets turnover frequency change 110 Figure 103 nearly four years Wenzhou peptide Kang Biotechnology Co., Ltd. Turnover of Working Capital changes 110 chart 104 nearly four years Wenzhou peptide Kang Biotechnology Co., Ltd. equity ratio changes of 111 Exhibit 105 nearly four years of Wenzhou peptide Kang Biotechnology Co., Ltd. equity ratio changes 111 Figure 106 nearly four years Wenzhou peptide Kang Biotechnology Co., Ltd. sales gross margin changes 111 chart for nearly four years, 107 Wenzhou peptide Kang Biotechnology Co., Ltd. sales gross margin change the situation 112 chart 108 nearly four years Wenzhou peptide Kang Biotechnology Co., Ltd. asset-liability ratio change 112 chart for nearly four years, Wenzhou peptide Kang Biotechnology Co., Ltd., asset-liability ratio changes 113 chart 110, 109 nearly four years Wenzhou peptide Uni-Bio Science Co., Ltd. Total asset turnover change 113 chart 111 nearly four years Wenzhou peptide Kang Biotechnology Co., Ltd. Turnover of total assets changes 114 chart 112 nearly four years Wenzhou peptide Kang Biotechnology Co., Ltd., the number of fixed assets turnover 114 chart for nearly four years, 113 Wenzhou peptide Kang Biotechnology Co., Ltd. fixed assets turnover frequency change 115 Figure 114 nearly four years Beijing Sheng Miele biotechnology limited liability company current assets turnover changes 116 chart for nearly four years, 115 the Beijing Sheng Miele biotechnology limited liability company current assets turnover number of changes in 116 Figure 116 nearly four years the Beijing Sheng Miele biotechnology limited liability company equity ratio changes 117 chart for nearly four years, 117 the Beijing Sheng Miele biotechnology limited liability company equity ratio changes 117 Figure 118 nearly four years Beijing Sheng Mei Connaught Biological Technology Co., Ltd. sales gross margin changes 117 Figure 119 nearly four years the Beijing Sheng Miele biotechnology limited liability company sales gross margin changes 118 Figure 120 nearly four years the Beijing Sheng Miele biotechnology limited liability company assets-liability ratio changes 118 Chart 121 nearly four years the Beijing Sheng Miele biotechnology limited liability company assets-liability ratio change 119 chart for nearly four years, 122 Beijing Sheng Miele biotechnology limited liability company's total asset turnover changes 119 chart 123 nearly four years Beijing Sheng the Miele biotechnology limited liability company's total assets turnover frequency changes 120 Figure 124 nearly four years Beijing Sheng Miele biotechnology limited liability company fixed assets turnover times 120 Figure 125 nearly four years Beijing Sheng Miele biotechnology limited liability company fixed assets turnaround times change 121 chart for nearly four years, 126 Biological Technology Co., Ltd. of Qingzhou Lombe current assets turnover frequency change of 122 Figure 127 nearly four years Qingzhou Lombe Biotechnology Co., Ltd. changes in current assets turnover of 122 Figure 128 nearly four years Qingzhou Long Tony Biotechnology Co., Ltd. equity ratio changes 123 Figure 129 nearly four years Qingzhou Lombe Biotechnology Co., Ltd. equity ratio changes 123 Figure 130 nearly four years Qingzhou the Lombe Biological Technology Co., Ltd. sales gross margin changes 123 Figure 131 nearly four years Biotechnology Co., Ltd. Qingzhou Lombe changes in the gross profit margin 124 chart for nearly four years, 132 the Qingzhou Lombe Biotechnology Co., Ltd. asset-liability ratio changes 124 chart Qingzhou the Lombe Biological Technology Co., Ltd. asset-liability ratio of nearly four years, 133 125 charts 134 nearly four years Biotech Co., Ltd. of Qingzhou Lombe Turnover of total assets changes 125 chart for nearly four years, 135 Biotechnology Co., Ltd. Qingzhou Lombe Turnover of total assets changes 126 chart 136 nearly four years Qingzhou Lombe biotechnology Limited Fixed asset turnover, 126 chart 137 nearly four years Qingzhou Lombe Biotechnology Co., Ltd. fixed assets turnover frequency change 126 chart for nearly four years 138 Times Technology Co., Ltd. Beijing heroic current assets turnover change 128 chart 139 nearly four years heroic era Science and Technology Co., Ltd. current assets turnover changes 129 chart 140 nearly four years the heroic era Technology Co., Ltd. equity ratio change 129 chart 141 nearly four years of heroic era of science and technology equity ratio change 129 chart 142 nearly four years Beijing heroic era gross profit margin changes of Science and Technology Co., Ltd. 130 chart for nearly four years, 143 the heroic era Technology Co., Ltd. sales gross margin changes 130 Figure 144 nearly four years Beijing the heroic era Technology Co., Ltd. asset-liability ratio changes 131 Figure 145 nearly four years of heroic Times Technology Co., asset-liability ratio changes 131 chart for nearly four years, 146 heroic era Technology Co., Ltd. Turnover of total assets changes 132 chart 147 nearly four years, the heroic era of science and technology Co., Ltd. Turnover of total assets changes 132 Exhibit 148 4 in Beijing heroic era of science and technology Co., fixed assets turnover number 133 chart heroic era of science and technology for nearly four years, 149 fixed assets turnover frequency change 133 chart 150 for 2013-2018, China's supply of small peptides predicted 147 chart 151 for 2013-2018, China the small peptides demand forecast chart 148 152 2013-2018 153 Chart 154 of small peptides industry in China development challenges faced 156 chart 155 the small peptides industry, intra-industry competition risk and control strategy the small peptide enterprise in China investment growth forecast 158 ??Exhibit 156 small peptides industry operational risks and control strategy 161 Exhibit 157 small peptide technology Application Notes Analysis 168 Figure 158 small peptides project investment considerations Figure 170 Figure 159 production and development of small peptides industry Note 172 chart the 160 small peptides sales Note matters 173